Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD30 chimeric antigen receptor T-cell therapy - Wuhan Bio Raid Biotechnology

Next Previous
Drug Profile

Anti-CD30 chimeric antigen receptor T-cell therapy - Wuhan Bio Raid Biotechnology

Alternative Names: Anti-CD30 CAR-T therapy - Wuhan Bio Raid Biotechnology

Latest Information Update: 28 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wuhan Bio-Raid Biotechnology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Lymphoproliferative disorders

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Lymphoproliferative disorders(Second-line therapy or greater) in China (Parenteral)
  • 31 Jan 2022 Zhejiang University in collaboration with Shanghai First Song Therapeutics plans a early phase I trial in Lymphoma (Second-line therapy or greater, In adults, In the elderly) (IV), In China, In February 2022 (NCT05208853)
  • 01 Jul 2019 Phase-I clinical trials in Lymphoproliferative disorders (Second-line therapy or greater) in China (Parenteral) (NCT04008394)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top